Best Practices in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): Expert Perspectives in Immunotherapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the US, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with HPV has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in past years, the prognosis for metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. 

Upon completion of this activity, participants will be able to:

  • Analyze recent clinical trial data on immunotherapies in the first-line treatment of metastatic head and neck squamous cell carcinoma (HNSCC)

  • Integrate immune checkpoint inhibitors into the management of patients with recurrent/metastatic HNSCC

  • Identify metastatic HNSCC patients who would potentially benefit from the use of checkpoint inhibitors

  • Examine strategies to optimally sequence immunotherapy regimens in metastatic HNSCC

  • Explore strategies to mitigate immune-related adverse events in patients with HNSCC receiving immunotherapy or multimodal combinations with immunotherapy components
     

Faculty: Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
UC San Diego Health
Co-director, San Diego Center for Precision Immunotherapy
Co-director, Head and Neck Cancer Center of Excellence
UC San Diego Moores Cancer Center

Disclosure:

Dr. Cohen has served as a consultant for Amgen, AstraZeneca, Bayer, BMS, Incyte, MSD, and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue